HOME >> MEDICINE >> NEWS
International breast cancer prevention study launches in the United States and Canada

Boston-March 30, 2005 Today, a new clinical trial evaluating a novel approach to breast cancer prevention launched in the United States and Canada. Called the ExCel research study, this is the first North American clinical trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer.

Coordinated by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), the ExCel research study will examine the potential benefit of exemestane and its ability to prevent breast cancer in women who are at increased risk for the disease. Exemestane part of a class of drugs called aromatase inhibitors suppresses estrogen production, a key component in the development of some types of breast cancer. Exemestane could provide women with an alternative option to tamoxifen, the only drug FDA approved for prevention of breast cancer.

"Breast cancer is a major public health issue every 30 seconds somewhere in the world a woman is diagnosed with this disease," says Dr. Paul Goss, the ExCel research study chair.

"Thousands of women have already beat breast cancer thanks to recent research on aromatase inhibitors. As a result, we think this could be an effective approach to preventing it from developing in the first place."

The ExCel research study will follow more than 4,500 postmenopausal women from the U.S., Canada and Spain over a five year period. To be eligible, women must be 35 years of age or older and have an increased risk of developing breast cancer. Risk factors can include a woman's age, her family history of breast cancer, her age at first menstrual period and her age at first live birth.

Initial results of the trial could be available within four years and study investigators hope to see as much as a two-thirds reduction in the incidence of breast cancer among women in the treatment group.

Aromatase inhibitors are currently being used to treat breast cancer in wo
'"/>

Contact: Samantha Kaplan
samantha.kaplan@edelman.com
312-297-7439
Edelman Public Relations
30-Mar-2005


Page: 1 2 3 4

Related medicine news :

1. National Academies advisory: May 2 Symposium on International Science Policy
2. Awards & fellowships at the International & American Association for Dental Research General Session
3. Lectures, keynoters, symposia highlight International Dental Research meeting
4. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
5. International gathering of experts to share retinoblastoma breakthroughs
6. International trial of two microbicides begins
7. International gathering at UH examines top computer code
8. International trial finds benefits of breast MRI in women at high risk
9. International study provides culture-by-culture clues to family violence and abuse
10. St. Jude scientist wins International Society of Experimental Hematology award
11. International MRC trial finds a routine treatment for head injury may do more harm than good

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology:
Cached News: